A study in the journal, Blood, explains how the peptide Ac2-26 flips a biological switch in immune cells in people with Sickle Cell Disease.
Scientists have found a way to lower stroke risk in Sickle Cell patients that opens a gateway of potential treatments for inflammation and clotting stemming from conditions such as Covid-19.